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Potential role of BRCA1 protein 
expression as a prognostic tissue 
biomarker in breast carcinoma: 
An immunohistochemical and 
clinicopathologic study from South India
ABSTRACT
Introduction. BRCA1 dysfunction is a hallmark of both hereditary and sporadic breast cancer. BRCA1 protein 
expression can be lost by germline mutation, somatic mutation or promoter hypermethylation. This study aimed 
to explore BRCA1 dysfunction in breast cancer patients by immunohistochemistry and to study its association 
with prognostic factors. 
Material and methods. BRCA1 protein expression was assessed by immunohistochemistry on formalin fixed 
paraffin embedded tissue blocks of 110 invasive breast carcinoma patients. Furthermore, the clinical findings 
and tumor features associated with BRCA1 dysfunction were characterized. 
Results. Reduced BRCA1 immunoreactivity was observed in 19% of breast cancer cases. Although these pa-
tients presented with aggressive tumor characteristics, statistical significance was observed only with presence 
of lymphovascular emboli (p < 0.05). These results suggest that loss of BRCA1 protein expression is associated 
with an aggressive phenotype of breast carcinoma. 
Conclusions. Immunohistochemistry for BRCA1 protein expression in tumor tissues may provide a less expensive 
screening tool to identify BRCA1 dysfunction due to genetic or epigenetic alterations. 
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Introduction
Breast cancer is a highly heterogeneous disease with 
different biological behaviors, therapeutic responses, 
and clinical outcomes among the various subtypes. The 
highly penetrant breast cancer susceptibility gene BRCA 
was discovered in the early nineties which accounts 
for almost 60% of hereditary breast cancers [1]. Our 
knowledge on breast carcinogenesis comprising of 
morphological, immunohistochemical and molecular 
characterization has improved ever since the discovery 
of these genes. 
BRCA1 gene is located on chromosome 17q21 which 
consists of 23 coding exons and encodes a nuclear 
protein with 1863 amino acids [2]. They are tumor 
suppressor genes encoding proteins that are essential 
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in the maintenance of genome stability through repair 
of double stranded DNA breaks by error free homolo-
gous recombination pathway. Therefore, cells that lack 
BRCA proteins are unable to repair these defects. This 
deficiency results in the repair of these DNA lesions by 
potentially mutagenic mechanisms such as non-homol-
ogous end joining and single- strand annealing. Several 
other genes like EMSY, RAD51C, ATM and Fanconi 
anemia genes are also involved in homologous recom-
bination mediated DNA repair. Pathogenic mutation in 
these genes is also associated with breast and ovarian 
cancer predisposition [3].
It is important to note that, in addition to germline 
BRCA1 gene mutations, BRCA protein deficiency can 
be seen in sporadic breast cancers due to somatic mu-
tations or epigenetic BRCA gene silencing as a conse-
quence of promoter hypermethylation [4]. This concept 
is referred to as BRCAness where histopathological 
and molecular features like triple negative phenotype 
will be similar to BRCA1/2 germline mutation-related 
breast cancers. Genetic aberrations in other homolo-
gous recombination-related genes could also lead to 
BRCAness [5].
Individuals are selected for genetic testing based 
on clinical characteristics where there is a high chance 
of missing potential germline mutation carriers due 
to small families, inheritance through unaffected men 
and development of tumors at an older age. Also 
genetic testing offered nowadays is time consuming 
and expensive. Moreover, this does not identify other 
mechanisms of BRCA protein deficiency. So the need 
arises to develop and validate new tissue biomarkers 
for the detection of BRCA dysfunction. Immunohisto-
chemistry is a cost-effective method which can be used as 
a screening test for the detection of BRCA dysfunction. 
Only very few studies have been done all over the world 
depicting loss of BRCA protein expression by immuno-
histochemistry. Studies using immunohistochemistry for 
genetic screening has not been conducted in Southern 
part of India so far.
The purpose of this study was to identify breast 
cancer patients with BRCA1 dysfunction by immuno-
histochemistry and to investigate its association with 
various clinicopathologic factors. This information 
obtained will help us in elucidating if clinical, morpho-
logical and immunohistochemical features could predict 
BRCA1 dysfunction in breast cancer.  
Material and methods
The present study was conducted over a period 
of one year between March 2019 and March 2020 in 
a Tertiary Care Center in Kerala, South India after 
obtaining approval from the Institutional Ethics Com-
mittee (PIMSRC/E1/388A/33/2014). This study was 
composed of 110 women with a diagnosis of breast 
carcinoma selected from the Department of Pathol-
ogy of the Institute. Patients with a histopathological 
diagnosis of invasive breast carcinoma were included 
in the study. Mesenchymal tumors, lymphomas, prior 
treatment elsewhere, those with recurrence and patients 
not consenting for genetic analysis were excluded from 
the study.
Informed consent was obtained from all the partici-
pants involved in the study. Epidemiological data such 
as age at diagnosis, personal history of cancer, family 
history of cancer were obtained from these patients using 
a prestructured questionnaire.
Histopathologic parameters such as tumor sub-
type and grade were evaluated using H&E stained 
slides. Tumor grade was assessed using the Nottingham 
histological score. 
Immunohistochemistry was performed on forma-
lin-fixed, paraffin-embedded tissue sections using 
anti-BRCA1 antibodies (Biogenex, Rabbit polyclonal 
antibody). Three micrometer-thick sections were 
obtained on charged slides and incubated at 60–70C 
for 30 minutes. This is followed by deparaffinization 
and hydration through descending grades of alcohol. 
Antigen Retrieval was done with TRIS EDTA buffer 
for 15–20 minutes. The slides were then rinsed in 
distilled water and Tris buffered saline 2 minutes 
each. An endogenous peroxidase blocking agent (3% 
H2O2) was added for 10 minutes on the section. The 
slides were incubated with primary antibody and were 
conjugated with streptavidin Horse Radish Peroxidase 
(HRP). Diaminobenzene tetrahydrochloride (DAB) 
was used as the chromogen. The slides were coun-
terstained with hematoxylin and examined under the 
microscopy. The reaction was considered positive if 
more than 10% of the cells showed distinctive nuclear 
staining [6]. The stromal cells served as internal posi-
tive control as they retain a normal copy of BRCA1.
Slides without the primary antibody were used as 
negative control. 
Hormone receptor (estrogen and progesterone) ex-
pression, HER2/neu overexpression and Ki-67 prolifera-
tion were also studied by immunohistochemical staining 
on formalin fixed paraffin embedded tissues. Estrogen 
and progesterone receptors were considered positive 
when ≥ 1% of cell nuclei were positively stained. For 
Her2/neu testing, only complete circumferential mem-
branous staining in >10% of tumor cells (score of 3) 
were considered positive. Ki67 was considered high if 
more than 20% of cells showed positive nuclear staining.
Clinical parameters studied included patient age at 
initial diagnosis, size of the tumor, status of regional 
lymph nodes and the number of lesions at the time of 
diagnosis. 
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Association between BRCA1 immunohistochemical 
status and clinicopathological factors were evaluated 
using Fisher's Exact Test and c2 test.
Results
Patient characteristics
Women studied were in the age group ranging 
from 31 to 96 years. Mean age at the time of visit was 
55.9 years (SD = 11.3). The highest number of breast 
cancer cases were in the age group 51–60 years which 
was around 35% followed by 29% each in the age group 
41–50years and above 60 years. Approximately 7% were 
diagnosed under 40 years of age. 
Family history of cancer was seen in six patients. One 
patient presented with two primary cancers. Ten patients 
presented with multifocal tumor in the same breast. 
Axillary lymph node metastasis was noted in 42% of 
cases. Tumor size more than 2 cm was observed in 75% 
of cases.
Histopathological characteristics
The predominant histological type was invasive carci-
noma of no special type (NST) which was seen in 89% of 
cases. Histological grading of the tumors was done which 
revealed 30% of grade 1 tumors, 51% grade 2 tumors and 
15% of grade 3 tumors. Metaplastic carcinoma of breast 
was not graded. Hormone receptor positivity was seen in 
68% of tumors. HER2/neu overexpression was observed 
in 16% of tumors. Seven percent of tumors were triple 
positive (ER+, PR+, HER2+ve) and 23% of tumors 
were triple negative (ER-, PR-, HER2-ve). Our study 
showed a high Ki67 expression in 54% of cases (Tab. 1).
BRCA1 immunohistochemistry findings
Of the 110 breast cancer cases, 19% (21/110) 
showed loss of BRCA1 expression and 81% (89/110) 
showed intact BRCA1 nuclear staining (Tab. 2). All the 
cases showed cytoplasmic positivity. Cases with intact 
BRCA1 staining showed moderate to strong staining 
in >10% of tumor nuclei (Fig. 1). Majority of the cases 
showed strong staining in more than 50% of tumor 
cells. Cases with loss of BRCA1 expression showed 
either complete absence of staining or weak staining 
in < 10% of tumor nuclei (Fig. 2). 
Clinical and histopathological characteristics of 
women with altered BRCA1 expression
Of the 21 breast cancer cases with loss of BRCA1 ex-
pression, nine were below 50 years of age. 11 patients 
with altered BRCA1 expression had axillary lymph 
Table 1. Clinical and pathological characteristics of the 
study participants
Parameters Number of 
cases (n = 110)
Percentage
Age at initial diagnosis
< 40 yrs 9 7%
41–50 yrs 31 29%
51–60 yrs 39 35%
> 61 yrs 31 29% 
Family history 6 5%
Lymph node metastasis 46 42%
Histological grade
Grade 1 33 30%
Grade 2 56 51%
Grade 3 16 15%
Histological type
Invasive breast carcinoma of 
no special type (NOS)
89 80%
Invasive carcinoma with 
medullary features
4 3.6%




































node metastasis. Fifteen patients presented with 
tumor size more than 2 cm. None of the cases had 
family history of cancer. The histological type seen in 
20 cases with altered BRCA1 expression was invasive 
carcinoma of no special type. Among the cases with 
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Table 2. Proportion of breast cancer patients with reduced 
BRCA1 expression
BRCA1 protein  
expression
Number of 
cases (n = 110)
Percentage
> 10% (Retained) 89 81%
< 10% (Loss) 21 19%
NORMAL BRCA1 IMMUNOREACTIVITY
Figure 1. Retained BRCA1 protein expression in tumor nuclei, 
40× (normal)
ALTERED BRCA1 IMMUNOREACTIVITY
Figure 2. Loss of BRCA1 protein expression in tumor nuclei, 
40× (abnormal)
loss of BRCA1 expression, 14 were grade 2 tumors 
and 5 grade 3 tumors. Triple negative breast cancer 
was observed in six cases and Her2/neu overexpression 
in two cases. Lymphovascular emboli was observed in 
9 cases. Ki 67 expression was high in sixteen cases with 
altered BRCA1 expression.
Statistical significance
It was observed that presence of lymphovascular 
emboli showed association with loss of BRCA1 expres-
sion statistically (p ≤ 0.05). All other clinicopathologic 
variables (family history, number of lesions, histological 
grade, stage, hormonal receptor and HER2/neu expres-
sion, Ki67) were not found to be statistically significant. 
Discussion
Breast cancer is the most commonly diagnosed 
cancer in females with an incidence of 2.3 million cases, 
representing 11.7% of all cancer cases and 6.9% of all 
cancer related deaths in 2020 [7]. The state of Kerala 
in South India has been seeing a rise in the number 
of breast cancer cases over the last few years [8]. 
Moreover, a good number of cases in India are seen 
in younger age groups when compared to women 
in western countries [9]. This stress the importance 
in identifying the cause for the current trend in the 
state. Genetic predisposition is one of the reasons for 
early onset breast cancer which is usually aggressive 
in nature. BRCA1 is the most commonly mutated 
gene in hereditary breast cancer. Genetic testing for 
germline mutation is not routinely done in most Indian 
centers due to the high cost involved. This has urged 
the need to identify and validate new tissue biomarkers 
for prognostic and therapeutic purposes. The role of 
BRCA1 protein in tumor tissues can be investigated in 
these patients by immunohistochemistry where genetic 
testing cannot be performed. Immunohistochemistry 
is a cost effective, easy to perform laboratory method 
to assess the expression of various proteins in tumor 
tissues for diagnosis, localization and detection of 
dysfunctional proteins. Several studies have also re-
ported other mechanisms such as somatic mutation 
and promoter hypermethylation for reduced BRCA 
protein expression in tumor tissues [10].
The benefit of identification of BRCA gene mutations 
has been well established over the years. Novel targeted 
therapies such as Poly-(ADP) ribose polymerase inhibitors 
(PARPi) and platinum based chemotherapeutic agents 
have been developed for BRCA associated cancers [11].
Olaparib and talazoparib are the PARP inhibitors currently 
approved for treatment in patients with advanced breast 
cancer associated with germline BRCA mutation [12]. 
Although the use of PARP inhibitors is currently restricted 
to germline BRCA mutated breast cancers, trials are 
underway evaluating its role in the management of breast 
cancers exhibiting BRCAness phenotype and homologous 
recombination deficiency [13]. Recent studies have shown 
promising results regarding the use of PARP inhibitors in 
sporadic breast cancers with BRCA dysfunction.
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Large number of studies have been done on BRCA 
gene mutation in breast cancer worldwide. However, 
BRCA1 protein expression in tumor tissues of breast 
cancer patients is less known. This study was therefore 
undertaken to assess the expression of BRCA1 protein 
in female breast cancer patients from Kerala and to 
investigate its association with clinical and pathological 
factors. The aim of this study was to detect BRCA1 dys-
function and identify tumor characteristics relating to 
dysfunction in formalin-fixed paraffin-embedded tissues.
In the current study, we identified 19% of women 
with altered BRCA1 protein expression in tumor tis-
sues. Majority of women showed intact BRCA1 stain-
ing in the tumor tissues. We observed both nuclear 
and cytoplasmic staining in all the cases. Our results 
also demonstrated that loss of BRCA1 expression was 
associated with aggressive tumor characteristics. The 
breast carcinomas with reduced BRCA1 expression were 
high grade tumors. Seventyone percent of cases with 
altered expression had large tumor size. Triple negative 
phenotype was observed in 29% of tumors with altered 
expression. Another interesting observation was that 
43% of women with reduced BRCA1 expression were 
below 50 years of age.
According to a recent study by Israa A Hussein et al. [14], 
BRCA1 protein expression was reduced in 79.5% which 
is quite high when compared to our study. They demon-
strated a significant relationship of BRCA status with 
advanced stage, higher grade of the tumor and hormone 
receptor negativity. Priyadarshini et al. reported absence 
of BRCA1 staining mostly in tumors of large sizes and 
with higher histologic grades [15]. These findings are in 
line with our study.
Deepti Verma et al. observed a significant asso-
ciation of reduced BRCA1 expression with HER2/neu 
positivity. We observed HER2/neu overexpression in 
10% cases with reduced expression. In addition, they 
also showed association of altered expression with large 
tumor size and high-grade tumors which was statisti-
cally significant [16]. These findings are similar to the 
observations seen in our study.  
Another study done in Portugal where BRCA1 im-
munohistochemistry was done using monoclonal anti-
bodies and was correlated with BRCA1/2 genetic screen-
ing results. This study showed loss of BRCA1 expres-
sion in 80% of cases with germline BRCA1 mutation 
indicating high specificity for the prediction of 
BRCA1 carriers with immunohistochemistry using 
monoclonal antibodies [17]. Different types of anti-
bodies for BRCA1 proteins are commercially available 
at present. Controversies regarding the subcellular 
localization of BRCA1 have been existing for the last 
few years. Formalin fixed paraffin embedded sections 
of breast cancer showed a variety of staining patterns 
ranging from predominantly nuclear, both nuclear and 
cytoplasmic and mainly cytoplasmic. This variability in 
the subcellular localization of BRCA1 protein could 
be due to the specificity of the antibodies used in vari-
ous studies to detect the protein. In our study we used 
a polyclonal antibody which showed both nuclear and 
cytoplasmic positivity.
Kazuaki Miyamoto et al. [4] observed reduced 
BRCA1 immnoreactivity in 62% of sporadic breast 
cancers where none of the cases harbored BRCA1 mu-
tations thereby showing other mechanisms like pro-
moter hypermethylation as the cause for the reduced 
expression. Another study by Hedau et al also observed 
a decline in the protein expression of BRCA1 in 50% 
of sporadic breast cancer cases [18].
Wen-Ying Lee [19] reported a higher incidence of 
loss of BRCA1 nuclear expression in younger women 
with breast cancer which was seen to be associated 
with large tumor size and high proliferation rate. This 
observation is consistent with our study findings where 
43% of the cases with reduced BRCA1 expression were 
below 50 years. 
Rakha et al. [20] showed complete loss of BRCA1 nu-
clear expression in 15% of breast cancer cases which 
was correlated with high-grade, advanced lymph node 
stage, larger size, vascular invasion, negative estrogen 
and progesterone receptor.
Similar findings were also observed in a Japanese study 
by Yoshikawa et al. [21] where 28% of sporadic breast 
cancer cases also showed reduced BRCA1 expression 
in addition to 79% of BRCA1 associated breast cancers.
Several studies have been done on BRCA1 protein 
expression in ovarian cancers also in the past. Accord-
ing to a study by J. L. Meisel et al. [22], BRCA1 im-
munohistochemistry was found to be abnormal in 36% 
of ovarian cancers of which 52% was due to germline 
mutation and the remaining due to somatic mutation 
and promoter hypermethylation. Two other similar stud-
ies done by Karuna Garg et al. and Tarinee Manchana 
et al. on ovarian cancer patients also showed loss of 
BRCA1 expression by immunohistochemistry in 47% 
and 20% of cases [23, 24].
Therefore, our study demonstrated BRCA1 dys-
function in tumor tissues of a subset of breast cancer 
cases which was seen to have tumor characteristics like 
higher grade, high proliferative index, large tumor size 
and presence of lymphovascular emboli. Reduction 
of BRCA1 protein expression may be considered as 
an additional prognostic factor. Our study indeed has 
limitations as we were unable to obtain the mutation 
status in these patients. It is imperative to conduct 
large scale studies to assess the clinical usefulness of 
immunohistochemistry as an alternative to the more 
expensive molecular testing especially in low resource 
settings and also to select patients likely to benefit from 
targeted therapies. 
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Conclusions
In summary, immunohistochemistry is a promising 
tool in detecting loss of BRCA1 protein expression 
which could be due to genetic or epigenetic altera-
tions. Reduced or loss of BRCA1 protein expression 
plays a significant role in the development of breast can-
cer. Majority of the cases with loss of protein expression 
presented with aggressive tumor characteristics. These 
findings indicate that there are tumor characteristics 
which suggest the presence of BRCA1 dysfunction in 
breast cancer patients. Thus, knowledge of BRCA1 ex-
pression in tissues could provide additional clinically 
relevant information in breast cancer patients.
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